BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 34642211)

  • 21. SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.
    Kolin DL; Dong F; Baltay M; Lindeman N; MacConaill L; Nucci MR; Crum CP; Howitt BE
    Mod Pathol; 2018 Sep; 31(9):1442-1456. PubMed ID: 29700418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
    Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
    Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
    Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
    Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of BRG1 (
    Saunders J; Ingley K; Wang XQ; Harvey M; Armstrong L; Ng T; Dunham C; Bush J
    Pediatr Dev Pathol; 2020; 23(2):132-138. PubMed ID: 31403913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.
    Schneppenheim R; Frühwald MC; Gesk S; Hasselblatt M; Jeibmann A; Kordes U; Kreuz M; Leuschner I; Martin Subero JI; Obser T; Oyen F; Vater I; Siebert R
    Am J Hum Genet; 2010 Feb; 86(2):279-84. PubMed ID: 20137775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SWI/SNF-deficient thoraco-pulmonary neoplasms.
    Sesboue C; Le Loarer F
    Semin Diagn Pathol; 2021 May; 38(3):183-194. PubMed ID: 33451916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
    Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
    Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
    Xue Y; Meehan B; Macdonald E; Venneti S; Wang XQD; Witkowski L; Jelinic P; Kong T; Martinez D; Morin G; Firlit M; Abedini A; Johnson RM; Cencic R; Patibandla J; Chen H; Papadakis AI; Auguste A; de Rink I; Kerkhoven RM; Bertos N; Gotlieb WH; Clarke BA; Leary A; Witcher M; Guiot MC; Pelletier J; Dostie J; Park M; Judkins AR; Hass R; Levine DA; Rak J; Vanderhyden B; Foulkes WD; Huang S
    Nat Commun; 2019 Feb; 10(1):558. PubMed ID: 30718512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
    Medina PP; Sanchez-Cespedes M
    Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.
    Zheng L; Zhang L; Wang XI; Katz G; Tandon N; Zhao B; Lucci J; Ding J; Zhang S
    Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
    Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N
    Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
    Jelinic P; Mueller JJ; Olvera N; Dao F; Scott SN; Shah R; Gao J; Schultz N; Gonen M; Soslow RA; Berger MF; Levine DA
    Nat Genet; 2014 May; 46(5):424-6. PubMed ID: 24658004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation].
    Le Quang M; Ranchère-Vince D; Le Loarer F
    Ann Pathol; 2019 Dec; 39(6):399-413. PubMed ID: 31255411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
    Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.
    Peng L; Li J; Wu J; Xu B; Wang Z; Giamas G; Stebbing J; Yu Z
    Front Immunol; 2021; 12():762598. PubMed ID: 34675941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coffin-Siris syndrome is a SWI/SNF complex disorder.
    Tsurusaki Y; Okamoto N; Ohashi H; Mizuno S; Matsumoto N; Makita Y; Fukuda M; Isidor B; Perrier J; Aggarwal S; Dalal AB; Al-Kindy A; Liebelt J; Mowat D; Nakashima M; Saitsu H; Miyake N; Matsumoto N
    Clin Genet; 2014 Jun; 85(6):548-54. PubMed ID: 23815551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type.
    Andrianteranagna M; Cyrta J; Masliah-Planchon J; Nemes K; Corsia A; Leruste A; Holdhof D; Kordes U; Orbach D; Corradini N; Entz-Werle N; Pierron G; Castex MP; Brouchet A; Weingertner N; Ranchère D; Fréneaux P; Delattre O; Bush J; Leary A; Frühwald MC; Schüller U; Servant N; Bourdeaut F
    J Pathol; 2021 Sep; 255(1):1-15. PubMed ID: 33999421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rhabdoid tumor predisposition syndrome.
    Sredni ST; Tomita T
    Pediatr Dev Pathol; 2015; 18(1):49-58. PubMed ID: 25494491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.
    Perret R; Chalabreysse L; Watson S; Serre I; Garcia S; Forest F; Yvorel V; Pissaloux D; Thomas de Montpreville V; Masliah-Planchon J; Lantuejoul S; Brevet M; Blay JY; Coindre JM; Tirode F; Le Loarer F
    Am J Surg Pathol; 2019 Apr; 43(4):455-465. PubMed ID: 30451731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.